(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 1.86% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.
Bioventus's revenue in 2025 is $573,280,000.On average, 1 Wall Street analysts forecast BVS's revenue for 2025 to be $46,298,956,261, with the lowest BVS revenue forecast at $46,298,956,261, and the highest BVS revenue forecast at $46,298,956,261. On average, 1 Wall Street analysts forecast BVS's revenue for 2026 to be $48,742,514,562, with the lowest BVS revenue forecast at $48,742,514,562, and the highest BVS revenue forecast at $48,742,514,562.
In 2027, BVS is forecast to generate $51,184,433,991 in revenue, with the lowest revenue forecast at $51,184,433,991 and the highest revenue forecast at $51,184,433,991.